Replimune Group Inc. stocks have been trading down by -15.79 percent following bearish sentiment around its latest clinical trial update.
Click Here for a Millionaire's POV on Trading REPL
SUBSCRIBE FOR ALERTSJOIN 50,000+ ACTIVE TRADERS
What Traders Need To Know
- The FDA issued a second Complete Response Letter for Replimune’s BLA for RP1 plus nivolumab in anti-PD-1-failed melanoma, again finding the pivotal IGNYTE trial inadequate to demonstrate effectiveness.
- Following the latest FDA rejection of RP1, Replimune’s stock collapsed by roughly 62–64% on massive volume as analysts concluded there is no clear regulatory path forward for the asset in melanoma.
- A wave of analyst downgrades hit the stock, with firms including H.C. Wainwright, Leerink, Wedbush, JPMorgan, Jefferies, Piper Sandler, and Cantor Fitzgerald cutting ratings and slashing price targets, many to the $2–$4 range.
- Jefferies reported that management will no longer develop RP1 absent accelerated approval, leaving the company’s forward path uncertain.
- Law firms Johnson Fistel and Pomerantz have launched investigations into potential securities-law violations, including whether Replimune misled investors about addressing the FDA’s prior concerns around RP1.
Weekly Update Apr 20 – Apr 24, 2026: On Sunday, April 26, 2026 Replimune Group Inc. stock [NASDAQ: REPL] is trending down by -15.79%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.
Healthcare industry expert:
Analyst sentiment – negative
Replimune (REPL) now trades as a distressed development-stage oncology name with its lead value driver effectively impaired. Q3 FY25 results show zero product revenue and a steep operating loss of ~$71m, with R&D at $53m and G&A at $19m, driving ROE below -90%. Cash and short-term investments of ~$269m, current ratio 5.6x, and modest leverage (total debt/equity 0.36x) provide runway, but free cash flow of -$66m per quarter implies heavy dilution or deep cost cuts ahead.
Technically, the stock has attempted to base in the low single digits after the post-CRL collapse. Over the recent five-week sequence, shares rebounded from ~1.90 to a 2.85 spike before pulling back to 2.40, indicating a fragile short-covering rally rather than sustainable accumulation. Intraday 5-minute action has shown fading upside volume above 2.70. The actionable level is $2.00: a decisive break below on rising volume signals renewed downside, while aggressive traders could trade bounces toward 2.70–2.85 as short-term resistance.
More Breaking News
- AIXI Stock Jumps As China Court Backs Key AI Patents
- ORC Rises Ahead Of Q1 Results And Dividend Watch
- Snap Stock Slides As Legal Heat, Downgrades Rattle Traders
- LIDR Stock Pops As AEye Adds Lucid Veteran Before Q1 Call
The second FDA Complete Response Letter for RP1 plus nivolumab in anti–PD-1-failed melanoma, broad analyst downgrades, target cuts to $2–4, and emerging securities investigations collectively erase RP1’s prior valuation anchor. Sector-wise, REPL now underperforms both Healthcare and Biotechnology & Life Sciences peers on risk-adjusted return, with an inferior catalyst profile and elevated regulatory overhang. Absent a credible pipeline reset, the risk/reward is unfavorable; fair value skews toward $1.50–2.00 with resistance at $2.75 and support near $1.75.
Quick Financial Overview
Replimune Group Inc. is trading in the low single digits after a violent reset. Weekly data show REPL closing near $2.09 on 2026/04/20, dipping to $1.90 the next day, then bouncing as high as $2.88 before settling around $2.40 by 2026/04/24. That snapback from sub-$2 to the mid‑$2s reflects short-covering and bargain hunting after the FDA shock, not a restored long-term story. Intraday, a 5‑minute candle with a $2.70 open and fade down toward $2.42 confirms supply hitting every push higher.
Under the surface, Replimune Group Inc. still carries real balance‑sheet strength but heavy operating burn. The company ended the 2025/12/31 quarter with $124.7M in cash and $269.1M including short‑term investments, against total liabilities of $123.1M and a current ratio of 5.6. That gives runway, but the quarter also showed a net loss of about $70.9M and operating cash outflow of roughly $65.9M, driving free cash flow to around -$66.1M. Key ratios back this picture: return on equity is deeply negative, and price‑to‑book sits just under 1x, implying the market is valuing REPL near its stated equity as faith in future RP1-driven upside has faded.
For traders, that mix means optionality with real risk. Enterprise value near $7.0M against more than $210.5M of common equity and $333.6M in assets screens like a distressed biotech where the main program has broken. Analysts now broadly rate the stock Hold with a mean target around $4, but several high‑profile cuts to $2 point to limited expected upside without a new catalyst. With management effectively pausing RP1 development and the FDA calling trial data inadequate, near‑term upside drivers are unclear. This sets up REPL as a high‑volatility, news‑driven trading vehicle rather than a stable growth story.
Conclusion
This is stock news, not investment advice. StocksToTrade News delivers real-time stock market updates tailored to highlight the key catalysts driving short-term price movements. Our coverage is designed for active traders and investors who thrive in fast-moving markets, with a focus on volatile sectors like penny stocks, AI stocks, Robinhood stocks and other momentum plays. From earnings reports and FDA approvals to mergers, new contracts, and unusual trading volume, we break down the events that can spark significant price action.
Looking to level up your trading game? Explore StocksToTrade, the ultimate platform for traders. With powerful tools designed for swing and day trading, integrated news scanning, and even social media monitoring, StocksToTrade keeps you one step ahead.
Check out our quick startup guide for new traders!
- How to Read Stock Charts: A Guide for Beginners
- Trading Plan: 6 Steps to Create One
- How To Create a Stock Watchlist
Ready to build your watchlists? Check out these curated lists:
Once your watchlist is set, take the next step and trade with confidence using StocksToTrade’s robust platform. Don’t miss out — grab your 14-day trial for just $7 and experience the edge you need to thrive in today’s fast-paced markets.